Allogene Therapeutics, Inc.
HealthcareNASDAQ:ALLO · NASDAQ Global Select
+$0.02 today
Vol 8.64M · Avg 10.07M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-65.3%
avg -27.1%
ROIC
-54.0%
avg -33.2%
ROA
-45.9%
avg -30.7%
Analysis
ROA is currently the strongest return metric at -45.9% versus its period average of -30.7%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
David D. Chang | Co-Founder, President, Chief Executive Officer & Director | $1.14M | — | 66 | $5.15M | 2.11% |
Zachary J. Roberts | Executive Vice President of Research & Development and Chief Medical Officer | $750,761.00 | — | 48 | $718,763.00 | 0.29% |
Arie S. Belldegrun | Co-Founder & Executive Chairman | $728,726.00 | — | 77 | $929,913.00 | 0.38% |
Geoffrey Parker | Executive Vice President & Chief Financial Officer | $707,000.00 | — | 61 | $1.25M | 0.51% |
Joshua A. Kazam | Co-Founder & Director | $47,000.00 | — | 49 | $47,700.00 | 0.02% |
Benjamin Beneski | Senior Vice President & Chief Technical Officer | — | — | 49 | $195,338.00 | 0.08% |
Earl Douglas | Senior Vice President, General Counsel, Compliance Officer & Corporate Secretary | — | — | 63 | $564,948.00 | 0.23% |
Annie Yoshiyama | SVP & Corporate Controller | — | — | 42 | $124,517.00 | 0.05% |
Christine Cassiano | Executive Vice President, Chief Corporate Affairs & Brand Strategy Officer | — | — | — | — | — |
Susan R. Lundeen | Chief People Officer | — | — | 60 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
14
$603,324.79
Net Sentiment
$603,324.79
Net selling
Most Active
Beneski Benjamin Machinas
5 transactions
1–10 of 14
Analysis
Insiders reported 0 buys worth $0.00 and 14 sells worth $603,324.79 over the last 12 months. That adds up to net selling of $603,324.79. Beneski Benjamin Machinas was the most active insider with 5 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A4 analysts |
| Revenue | N/A | N/A | N/A | +20.4% (9yr)4 analysts |
| Net Income | N/A | N/A | N/A | N/A4 analysts |
| EBIT | N/A | N/A | N/A | N/A4 analysts |
Analysis
Forward estimates point to Revenue at +20.4% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Achieve Life Sciences, Inc.
NASDAQ:ACHV
$566.68M
Cabaletta Bio, Inc.
NASDAQ:CABA
$490.79M
Atea Pharmaceuticals, Inc.
NASDAQ:AVIR
$359.32M
Vanda Pharmaceuticals Inc.
NASDAQ:VNDA
$353.00M
Kyverna Therapeutics, Inc.
NASDAQ:KYTX
$352.74M
Editas Medicine, Inc.
NASDAQ:EDIT
$244.75M
Voyager Therapeutics, Inc.
NASDAQ:VYGR
$211.47M
Humacyte, Inc.
NASDAQ:HUMA
$177.24M
Caribou Biosciences, Inc.
NASDAQ:CRBU
$158.19M
Immutep Limited
NASDAQ:IMMP
$53.60M
Who manages ALLO?
Allogene Therapeutics, Inc. (ALLO) lists 10 active executives. The top listed executive is Arie S. Belldegrun, Co-Founder & Executive Chairman.
Are ALLO insiders buying or selling?
Recent insider activity shows net buying of $106.10M.
Explore More
Continue the stock analysis
Jump to another research area for this company.